Diabetes pill rybelsus tested in everyday clinics: does it work outside trials?
NCT ID NCT05443334
First seen Sep 30, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This completed study followed 465 adults with type 2 diabetes in Spain who were already prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar (HbA1c), body weight, and how satisfied patients were with the treatment over 8-10 months. The goal was to see how well the drug works in real-world settings, not just in controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Master Centre for Spain
Barcelona, 08025, Spain
-
Master Centre for Spain
Madrid, 28033, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Rybelsus)
What this could lead to
If successful, this study could confirm that oral semaglutide helps manage blood sugar and weight in everyday clinical practice, supporting its use for type 2 diabetes.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only how a marketed drug performs in routine care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.